Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/37843| Title: | HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors | Authors: | CUPPENS, Kristof Baas, Paul GEERDENS, Ellen Cruys, Bert FROYEN, Guy Decoster, Lynn THOMEER, Michiel MAES, Brigitte |
Issue Date: | 2022 | Publisher: | Source: | Lung cancer, 170 | Abstract: | Immune checkpoint inhibitors (ICIs) improved outcomes in non-small cell lung cancer (NSCLC) patients. We report the predictive utility of human leukocyte antigen class I (HLA-I) diversity and tumor mutational burden (TMB) by comprehensive next-generation sequencing. | Keywords: | HED;HLA-I diversity;HLA-I evolutionary divergence;Non-small cell lung cancer;PD-1 immunotherapy;TSO500;Tumor mutational burden | Document URI: | http://hdl.handle.net/1942/37843 | ISSN: | 0169-5002 | e-ISSN: | 1872-8332 | DOI: | 10.1016/j.lungcan.2022.05.019 | ISI #: | 000861749300001 | Datasets of the publication: | 10.1016/j.lungcan.2022.05.019 | Rights: | 2022 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2023 |
| Appears in Collections: | Research publications |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 1-s2.0-S0169500222004640-main.pdf | Published version | 3.68 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.